ASCOGastrointestinal19
TARGET AUDIENCE OVERVIEW OF ACTIVITY These proceedings from a CME symposium during the 2019 ASCO Annual Meeting explore the most significant therapeutic advances in the field of GI cancers by using the perspectives of leading experts on challenging cases and questions submitted by clinicians in the community to frame a relevant discussion of how this information has aided in the refinement of current routine clinical practice and ongoing research. This CME activity will help medical oncologists and other allied healthcare professionals find answers to the individualized questions and concerns that they frequently encounter and in turn provide high-quality cancer care. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CREDIT DESIGNATION STATEMENT AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC) HOW TO USE THIS CME ACTIVITY CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Professor Dirk Arnold, MD, PhD No relevant conflicts of interest to disclose. Tanios Bekaii-Saab, MD Advisory Committee: Amgen Inc, Immuneering Corporation, Imugene; Consulting Agreements: AbbVie Inc, Array BioPharma Inc, Bayer HealthCare Pharmaceuticals; Contracted Research: Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc, Bristol-Myers Squibb Company, Genentech, Ipsen Biopharmaceuticals Inc, Novartis; Data and Safety Monitoring Board/Committee: ARMO BioSciences, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Merck, SillaJen. Joseph Chao, MD Advisory Committee: Daiichi Sankyo Inc, Merck, Taiho Oncology Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boston Biomedical Inc, Foundation Medicine, Lilly; Contracted Research: Merck, Novonco Therapeutics Inc; Speakers Bureau: Merck. Anthony El-Khoueiry, MD Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, CytomX Therapeutics, Eisai Inc, EMD Serono Inc, Exelixis Inc, Merck, Pieris Pharmaceuticals Inc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP. Richard S Finn, MD Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Genentech, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Bristol-Myers Squibb Company, Eisai Inc, Genentech, Merck, Pfizer Inc, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Yelena Y Janjigian, MD Advisory Committee: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Imugene, Lilly, Merck, Merck Serono, MJH Associates Inc, Pfizer Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, Lilly, Merck, Roche Laboratories Inc. Scott Kopetz, MD, PhD Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Genentech. Eileen M O’Reilly, MD Consulting Agreements: Aptus Pharma, BioLineRx, Bristol-Myers Squibb Company, Celgene Corporation, CytomX Therapeutics, Gilead Sciences Inc, Halozyme Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, NewLink Genetics, Pfizer Inc, PharmaCyte Biotech, Pharmacyclics LLC, an AbbVie Company, Pieris Pharmaceuticals Inc, Sanofi Genzyme, Silenseed Ltd, Sobi, Targovax, twoXAR; Contracted Research: Acta Biológica, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Halozyme Inc, MabVax Therapeutics Inc, OncoQuest Inc, Roche Laboratories Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Celgene Corporation, Eisai Inc, Exelixis Inc, Genentech, Ipsen Biopharmaceuticals Inc, Lilly, Merck and Taiho Oncology Inc. Hardware/Software Requirements: Release date: July 2019 |